Previous Close | 59.71 |
Open | 60.16 |
Bid | 24.59 x 1000 |
Ask | 0.00 x 900 |
Day's Range | 59.54 - 62.39 |
52 Week Range | 55.16 - 76.70 |
Volume | |
Avg. Volume | 506,980 |
Market Cap | 5.279B |
Beta (5Y Monthly) | 1.14 |
PE Ratio (TTM) | 24.54 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2022. First Quarter 2022 Highlights Revenues of $376.6 million increased 4.6% on a reported basis and 5.6% on an organic basis compared to the prior year.GAAP earnings per diluted share of $0.39, compared to $0.53 in the first quarter of 2021; adjusted earnings per diluted
PRINCETON, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2022 financial results on Wednesday, April 27, 2022, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. The live call is accessible by dialing (800)-289-0720 and using the passcode 5706502. A simultaneous webcast of the call will
The Next Generation of Nerve Conduits NeuraGen 3D Nerve Guide Matrix NeuraGen 3D Guide Matrix, a resorbable implant for the repair of peripheral nerve discontinuities. PRINCETON, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company and pioneers in nerve repair, today announced the launch of NeuraGen® 3D Nerve Guide Matrix, a resorbable implant for the repair of peripheral nerve discontinuities. NeuraGen 3D i